^
    CANCER:

    HER2 Positive Breast Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    HER2 inhibitor
    trastuzumab
    margetuximab
    LZM-005
    trastuzumab + LZM-005
    trastuzumab-pkrb
    Hervelous (trastuzumab biosimilar)
    tucatinib
    trastuzumab-anns
    trastuzumab-dkst
    TX05 (trastuzumab biosimilar)
    trastuzumab-dttb
    trastuzumab-qyyp
    		0
    HER2 inhibitor
    KN026
    trastuzumab + tucatinib
    Zercepac (trastuzumab biosimilar)
    ZW25
    EG12014 (trastuzumab biosimilar)
    ZN-A-1041
    inetetamab
    DZD1516
    Hercease (trastuzumab biosimilar)
    HERtiCAD (trastuzumab biosimilar)
    trastuzumab-IFN-β mutein
    VRN101099
    trastuzumab
    AB-201
    trastuzumab + pertuzumab
    pertuzumab + trastuzumab-pkrb
    		1
    HER2 inhibitor, HER2 dimerization inhibitor
    pertuzumab / trastuzumab / hyaluronidase-zzxf
    pertuzumab + trastuzumab-dttb
    pertuzumab + inetetamab
    pertuzumab + Zercepac (trastuzumab biosimilar)
    2
    Selective estrogen receptor degrader
    Selective estrogen receptor degrader
    fulvestrant
    trastuzumab + abemaciclib
    palbociclib + tucatinib
    		3
    HER2 inhibitor, CDK4 inhibitor, CDK6 inhibitor
    palbociclib + ZW25
    trastuzumab + palbociclib
    abemaciclib + tucatinib
    tucatinib + PRT3645
    4
    Estrogen receptor antagonist
    tamoxifen
    5
    mTOR inhibitor
    everolimus
    fam-trastuzumab deruxtecan-nxki
    		6
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    BL-M07D1
    BNT323
    SHR-A1811
    7
    HER2 dimerization inhibitor
    QL1209 (pertuzumab biosimilar)
    pertuzumab
    8
    HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor
    poziotinib
    9
    PIK3CA inhibitor, HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab + alpelisib
    10
    Thymidylate synthase inhibitor
    capecitabine
    tegafur / uracil
    11
    Aromatase inhibitor
    Aromatase inhibitor
    letrozole
    12
    HER2-targeted antibody-drug conjugate, Tubulin inhibitor
    A166
    13
    PD1 inhibitor
    pembrolizumab
    14
    PD-L1 inhibitor
    avelumab
    15
    HER2-targeted antibody-drug conjugate, DNA replication inhibitor
    trastuzumab duocarmazine
    16
    HER2 inhibitor, mTOR inhibitor
    trastuzumab + everolimus
    sirolimus + inetetamab
    CDK4 inhibitor + CDK6 inhibitor
    		17
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    TQB3616
    PRT3645
    trastuzumab + lapatinib
    		18
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    trastuzumab + S-222611
    19
    HER2 inhibitor, PD1 inhibitor
    pembrolizumab + trastuzumab
    camrelizumab + inetetamab
    20
    HER2 inhibitor, HER3 inhibitor
    trastuzumab + MCLA-128
    21
    Multi-tyrosine kinase inhibitor
    anlotinib
    22
    Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel
    23
    VEGF-A inhibitor
    bevacizumab
    24
    PI3K inhibitor
    MEN1611
    25
    Topoisomerase II inhibitor, DNA inhibitor
    etoposide oral
    26
    PARP inhibitor
    olaparib
    27
    VEGFR-2 inhibitor, HER2 inhibitor
    trastuzumab + rivoceranib
    28
    Tubulin polymerization promoter, DNA synthesis inhibitor
    carboplatin + gemcitabine
    29
    Microtubule inhibitor
    E7389-LF
    30
    Tubulin polymerization promoter, Bcl2 inhibitor, Tubulin inhibitor
    carboplatin + albumin-bound paclitaxel
    31
    EGFR inhibitor
    Hemay022
    32
    Topoisomerase II inhibitor, HER2-targeted antibody-drug conjugate
    MM-302
    33
    PIK3CA inhibitor, HER2 inhibitor
    trastuzumab + alpelisib
    34
    Topoisomerase II inhibitor
    epirubicin
    doxorubicin hydrochloride
    35
    CDK4 inhibitor
    PF-07220060
    36
    DNA methylation inhibitor
    azacitidine
    37
    AKT inhibitor
    MK-2206
    38
    VEGFR-2 inhibitor
    rivoceranib
    39
    VEGF-A inhibitor, HER2 inhibitor
    bevacizumab + trastuzumab
    40
    PIK3CA inhibitor, HER2 inhibitor, HER3 inhibitor
    trastuzumab + alpelisib + LJM-716
    41
    AXL inhibitor, HER2 inhibitor
    trastuzumab + TP-0903
    TCHP
    TCbHP
    PH-FECH
    THP
    AC
    TC
    TCH
    		42
    Chemotherapy
    AC-TH
    AC-THP
    Nab-PHP + PldCHP
    EC-TH
    PCbTP
    TH
    VIP
    ECP-THP
    43
    FAK inhibitor
    FAK inhibitor
    44
    HER2-targeted CAR-T immunotherapy
    HER2-targeted CAR-T immunotherapy
    45
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    46
    HER2 inhibitor, Erythropoiesis stimulating agent
    HER2 inhibitor + Erythropoiesis stimulating agent
    47
    MUC1 inhibitor
    MUC1 inhibitor
    48
    Aromatase inhibitor, HER2 inhibitor
    HER2 inhibitor + Aromatase inhibitor
    49
    CDK8 inhibitor
    CDK8 inhibitor
    50
    CDK19 inhibitor
    CDK19 inhibitor
    ado-trastuzumab emtansine
    disitamab vedotin
    DP303c
    PF-06804103
    ARX788
    TAA013
    		51
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    ZW49
    ALT-P7
    MEDI4276
    IKS014
    MRG002
    BAT8001
    MF-TTZ-MMAE
    pyrotinib
    neratinib
    afatinib
    		52
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    trastuzumab + pyrotinib
    trastuzumab + neratinib
    pyrotinib + inetetamab
    ASLAN001
    53
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor, HER2 dimerization inhibitor
    pertuzumab + ado-trastuzumab emtansine
    54
    HER2 inhibitor, PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
    PF-05212384 + trastuzumab-pkrb
    pyrotinib + dalpiciclib
    		55
    HER2 inhibitor, HER4 inhibitor, CDK4 inhibitor, EGFR inhibitor, CDK6 inhibitor
    trastuzumab + palbociclib + pyrotinib
    palbociclib + neratinib
    56
    PD1 inhibitor, HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    nivolumab + fam-trastuzumab deruxtecan-nxki
    57
    HER2 inhibitor, HER4 inhibitor, HER2-targeted antibody-drug conjugate, EGFR inhibitor, Microtubule inhibitor
    neratinib + ado-trastuzumab emtansine
    58
    Tyrosine kinase inhibitor, Thymidylate synthase inhibitor
    Tyrosine kinase inhibitor + capecitabine
    59
    PD1 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    pembrolizumab + ado-trastuzumab emtansine
    disitamab vedotin + zimberelimab
    60
    HER2 inhibitor, CDK4 inhibitor, CDK6 inhibitor, HER2 dimerization inhibitor
    trastuzumab + palbociclib + pertuzumab
    61
    HER3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    U3-1402
    62
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    63
    HER2 inhibitor, PI3K inhibitor
    trastuzumab + MEN1611
    64
    VEGF-A inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    bevacizumab + disitamab vedotin
    65
    CD137 agonist, HER2 inhibitor
    PRS-343
    66
    HER2 inhibitor, PD1 inhibitor, LAG-3 inhibitor
    margetuximab + MGD013
    67
    HER2 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    ado-trastuzumab emtansine + tucatinib
    tucatinib + disitamab vedotin
    68
    Topoisomerase II inhibitor, HER2 inhibitor, HER2-targeted antibody-drug conjugate
    trastuzumab + MM-302
    69
    Topoisomerase II inhibitor, Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel + doxorubicin hydrochloride
    70
    HER2 inhibitor, JAK1 inhibitor, JAK2 inhibitor
    trastuzumab + ruxolitinib
    71
    HER2 inhibitor, CD20 inhibitor
    trastuzumab + TQB2303 (rituximab biosimilar)
    72
    HER2 inhibitor, HER2-targeted antibody-drug conjugate, EGFR inhibitor, Microtubule inhibitor
    lapatinib + ado-trastuzumab emtansine
    73
    Protein synthesis inhibitor, HER2 inhibitor
    MT-5111
    74
    PD-L1 inhibitor, HER2 inhibitor
    trastuzumab + atezolizumab
    75
    PD-L1 inhibitor, HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + atezolizumab + pertuzumab
    76
    HER2 inhibitor, CTLA4 inhibitor
    trastuzumab + tremelimumab
    77
    HER2 inhibitor, PD1 inhibitor, HER2 dimerization inhibitor
    pembrolizumab + pertuzumab + trastuzumab-qyyp
    78
    Aromatase inhibitor, HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    pyrotinib + letrozole
    79
    PD-L1 inhibitor, HER2 inhibitor, CTLA4 inhibitor
    KN046 + KN026
    80
    β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor, Chemotherapy
    HP + eribulin mesylate
    81
    CDK4 inhibitor, HER2-targeted antibody-drug conjugate, CDK6 inhibitor, Microtubule inhibitor
    palbociclib + ado-trastuzumab emtansine
    82
    PIK3CA inhibitor, HER2 inhibitor, PI3Kδ inhibitor
    trastuzumab + copanlisib
    83
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    84
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor, PARP inhibitor
    ado-trastuzumab emtansine + talazoparib
    85
    HER2 inhibitor, PARP inhibitor
    trastuzumab + talazoparib
    86
    Bcr-abl tyrosine kinase inhibitor, HER2 inhibitor, EGFR inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + lapatinib
    87
    ATR inhibitor, HER2-targeted antibody-drug conjugate, PARP inhibitor, Topoisomerase I inhibitor
    olaparib + fam-trastuzumab deruxtecan-nxki + BAY 1895344
    88
    HER2 inhibitor, WEE1 inhibitor
    trastuzumab + ZN-c3
    89
    WEE1 inhibitor
    ZN-c3
    acalabrutinib
    		90
    BTK inhibitor
    zanubrutinib
    ibrutinib
    91
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    92
    CDK19 inhibitor, CDK8 inhibitor
    RVU120
    93
    YES1 inhibitor, Src kinase inhibitor
    NXP900
    94
    CYP51A1 inhibitor
    itraconazole
    95
    HER2 inhibitor, HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki + tucatinib
    96
    PKC inhibitor
    AEB071
    97
    Bcr-abl tyrosine kinase inhibitor, HER2 inhibitor, HER4 inhibitor, EGFR inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + neratinib
    98
    β-tubulin inhibitor, α-tubulin inhibitor
    VERU-111
    99
    mTOR inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    everolimus + ado-trastuzumab emtansine
    100
    Microtubule stabilizer, Tubulin polymerization promoter, Sortilin inhibitor
    TH 1902
    101
    SIRPA inhibitor, STAT3 inhibitor, HER2-targeted antibody-drug conjugate, TNF inhibitor, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki + INB03
    102
    PD-L1 inhibitor, DNA synthesis inhibitor, DNA cross linking agent
    PD-L1 inhibitor + oxaliplatin
    103
    NRF2 inhibitor
    brusatol
    104
    PD-L1 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    atezolizumab + ado-trastuzumab emtansine
    105
    HER2 inhibitor, CD47 inhibitor, HER2 dimerization inhibitor
    pertuzumab + D3L-001
    106
    HER2 inhibitor, CD47 inhibitor
    D3L-001
    trastuzumab + GS-4721
    107
    HER2 inhibitor, CDK4 inhibitor, EGFR inhibitor, CDK6 inhibitor
    palbociclib + lapatinib
    108
    PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
    PF-05212384
    109
    PIK3CA inhibitor, HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    alpelisib + pyrotinib
    110
    HER2 inhibitor, α radiation emission
    BAY2701439
    111
    AKT inhibitor, p70S6K inhibitor
    CCT128930
    112
    HER2-targeted antibody-drug conjugate, NMT inhibitor
    MYX2449
    113
    HER2 degrader
    CH7C4
    114
    HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
    entinostat
    115
    HER2 inhibitor, HER4 inhibitor, MEK inhibitor, EGFR inhibitor
    trametinib + neratinib
    116
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy
    117
    HER2 inhibitor, HER4 inhibitor, mTOR inhibitor, EGFR inhibitor
    everolimus + neratinib
    118
    ATM kinase inhibitor
    AZD1390
    119
    PIK3CA inhibitor
    LX-086
    120
    PP2A inhibitor
    LB-100
    121
    HER2 inhibitor, HER4 inhibitor, HER2-targeted antibody-drug conjugate, EGFR inhibitor, Topoisomerase I inhibitor
    neratinib + fam-trastuzumab deruxtecan-nxki
    122
    Melanotransferrin modulator, HER2-targeted antibody-drug conjugate
    BT2111
    123
    PARP1 inhibitor, HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki + AZD5305
    124
    PD-L1 inhibitor, HER2 inhibitor, PD1 inhibitor
    trastuzumab + BMS-202
    125
    Topoisomerase II inhibitor, DNMT inhibitor
    doxorubicin hydrochloride + decitabine
    126
    Estrogen receptor antagonist, HER2 inhibitor, Selective estrogen receptor degrader
    HER2 inhibitor + OP-1250
    HER-2 positive
    HER-2 expression
    HER-2 amplification
    HER-2 overexpression
    HER-2 amplification + HER-2 L755S
    HER-2 A1170P
    HER-2 mutation
    HER-2 L768S
    HER-2 Q680R
    HER-2 R647K
    p95HER2 mutation
    HER-2 I655V
    HER-2 V773L
    HER-2 K753E
    HER-2 C634R
    HER-2 L755S
    HER-2 L869R
    HER-2 exon 20 insertion
    HER-2 K676R
    HR positive
    ESR1 wild-type + HR positive
    HR negative
    ER positive + PGR positive
    PIK3CA mutation
    PIK3CA E545
    PIK3CA G1049R
    PIK3CA M1043I
    PIK3CA H1047
    PIK3CA E542K
    PIK3CA Q546
    PIK3CA E542Q
    PIK3CA H1047R
    PIK3CA amplification
    PIK3CA N345K
    PIK3CA H1047L
    PIK3CA E453K
    PIK3CA wild-type
    PIK3CA K111N
    PIK3CA E545K
    PIK3CA I391M
    PIK3CA mutation + HR negative
    ER positive
    ER negative
    ER overexpression
    FCGR3A 158F
    FCGR3A 158V
    PD-L1 underexpression
    PD-L1 expression
    PD-L1 elevation
    ABCB1 G2677T
    ABCB1 C3435T
    ABCB1 C1236T
    ABCB1 G1236T + ABCB1 G2677T
    EGFR expression
    ERBB3 expression
    ACTA2 elevation
    PTEN deletion
    PD-1 overexpression
    ADRB2 overexpression
    MYBL2 overexpression
    HER-2 amplification + ER positive + PGR negative
    PIK3CA mutation + HR positive
    PIK3CA exon 20 mutation + HR positive
    HR-positive + PIK3CA wild-type
    HR positive + HER-2 amplification
    HR positive + HER-2 mutation
    ACTA2 overexpression
    PTEN expression
    ERBB3 E952Q
    PTEN rs701848
    YAP1 overexpression
    YAP1 underexpression
    POLE E790Q + ERBB2 amplification + TMB-H
    AKT2 expression
    KIR3DL2 mutation
    TGFBI promoter hypermethylation
    HR positive + BRCA positive
    MUC1 elevation
    miR-221 underexpression
    miR-21 overexpression
    VHL mutation
    KMT2B mutation
    MUC16 mutation
    BARD1 T351T
    IL6 elevation
    TNFA elevation
    IL18 elevation
    PIK3R1 EY451delinsD
    MLL2 mutation
    miR-125b-2 underexpression
    FGFR1 amplification
    AXL-L
    AR overexpression
    CDK12 amplification
    NRG1 overexpression
    HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K
    RAD21 mutation
    TMB-H + HER-2 positive
    PGR positive
    MSI-H/dMMR + TMB-H
    WBP2 overexpression
    POLE mutation + PD-L1 negative + TMB-H
    PPM1D mutation
    TMEM45B overexpression
    VEGFA overexpression
    MAF1 overexpression
    RRM2 overexpression
    BAG1 overexpression
    GRB7 overexpression
    miR-125b-2 expression
    RAD21 amplification
    MUC1 expression
    miR-221 expression
    PGR overexpression
    Rbsig overexpression
    Low PLR
    MAF1 expression
    CXXC5 overexpression
    SMO mutation
    SMARCB1 mutation
    MLH1 mutation
    SPP1 elevation
    miR-155 expression
    DLD overexpression
    High PLR
    High MLR
    High NLR
    MDM4 mutation
    MYC amplification
    MUC4 expression
    ANXA1 expression
    ERBB4 H809G + ER positive
    MYC amplification + HER-2 amplification
    MYC mutation
    TP53 mutation
    RET fusion + TP53 mutation
    CDYL2 overexpression
    CD36 overexpression
    miR-98-5p underexpression
    IGF2 overexpression
    MAPT overexpression
    SLC39A6 overexpression
    MALAT1 overexpression
    YES1 amplification
    ATM mutation
    NCAPG overexpression
    NDUFA4L2 overexpression
    CUL7 overexpression
    STAT6 underexpression
    PPP2R2B underexpression
    XRCC1 overexpression
    miR-101-5p overexpression
    ERCC1 overexpression
    HRD
    TROP2 expression
    ERCC1 negative
    LDH elevation
    BCL6 overexpression
    IL21R overexpression
    CDKN2A deletion
    HER-2 amplification + AXL expression
    STAT6 deletion + HER-2 overexpression
    RAB5A expression
    ER negative + PIK3CA H1047R
    TCEAL9 overexpression
    IGF1R amplification
    PTPN2 amplification
    MET amplification
    HGF amplification
    BIRC5 overexpression
    ERBB4 expression
    miR-155 overexpression
    miR-1246 overexpression
    CD47 positive
    TSC2 C1450G
    SPP1 mutation